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Cells for Therapeutic Use:  
Celltex Therapeutics’ Partnership 
with RNL Bio, Substantial Medical 
Risks, and the Implications of United 
States v. Regenerative Sciences* 
Katherine Drabiak-Syed† 
Abstract 
This Article examines the convergence of three corporations that have 
attempted to capitalize on translating emerging research into clinical 
procedures by manufacturing and facilitating the process for patients to 
obtain mesenchymal stem cell (MSC) injections. Although the Food and 
Drug Administration (FDA) has asserted its authority to regulate somatic 
cell therapy products like MSCs under the Public Health Service Act and 
the Food, Drug, and Cosmetic Act, some manufacturers have attempted 
to circumvent FDA regulation through various mechanisms and argue 
that their products do not fall within the definition of a biological product 
or drug. However, scientific knowledge of using MSCs for clinical therapy 
remains in its infancy, and MSCs pose a number of serious risks to 
patients. This Article focuses on the development of Celltex, a company 
based in Sugar Land, Texas that manufactures and facilitates the injection 
of autologous MSCs; RNL Bio, a company that licenses its operations 
technology to Celltex; and Regenerative Sciences, a company based in 
Broomfield, Colorado that was recently involved in litigation with the 
FDA. Corporate circumvention of intended regulatory oversight exposes 
patients to potentially inefficacious products that could contribute to 
serious medical injuries such as viruses, myocardial infarction, cancer, or 
death. 
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Introduction 
Over the past few years, a growing number of companies have started 
to offer patients purported treatment for various diseases and conditions 
using autologous adult stem cells (ACSs) for non-homologous purposes—
specifically mesenchymal stem cells (MSCs) derived from the patient’s 
own adipose tissue.1 This Article examines the convergence of three 
corporations that have attempted to capitalize on translating emerging 
research into clinical procedures by manufacturing and facilitating the 
 
1. This Article will refer to non-blood stem cells (mesenchymal) derived from 
an individual and prepared for use in that same individual (autologous) 
and intended to serve a different medical purpose (non-homologous). 
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process for patients to obtain mesenchymal stem cell (MSC) injections.2 
The FDA has asserted its authority to regulate somatic cell therapy 
products, including MSCs, under the Public Health Service Act (PHSA) 
and the Food, Drug, and Cosmetic Act (FDCA), but some manufactur-
ers have attempted to circumvent FDA regulations through various 
strategies—namely, by arguing that their products do not fall within the 
definition of a “drug” so the corporation need not follow the require-
ments set forth in the FDCA prior to advertising the product for 
treatment purposes. This Article examines: (1) the development of 
Celltex, a company that manufactures and facilitates the injection of 
autologous MSCs; (2) RNL Bio, the company that licenses its operations 
technology to Celltex; and (3) recent litigation between the FDA and 
Regenerative Sciences. 
ASCs are unspecialized multi-potent cells that are capable of renewing 
themselves through cell division and differentiating into different types 
of cells.3 Unlike pluripotent cells, which are capable of differentiating 
into all tissues of the patient, ASCs are more limited in their ability to 
differentiate.4 They can be derived through sources such as bone marrow, 
muscle, skin, and teeth; more recently, scientists have begun extracting 
and isolating them from adipose tissue.5 Despite ASCs’ anticipated 
potential for clinical therapies, the scientific community is just beginning 
to understand their efficacy and safety.6 In addition to uncertain benefit, 
the manipulation and injection of stem cells poses a number of risks 
arising from inherent properties of the cells and the method of manufac-
ture.  
Part I of this Article describes the development of Celltex and its 
connection to Texas Governor Rick Perry and outspoken physician and 
Celltex co-founder Dr. Stanley Jones. This section explores Celltex’s 
connection to RNL Bio and describes the initial media coverage relating 
to Celltex’s practices. Part II provides an overview of sections of the 
PHSA and the FDCA pertaining to the manufacture of MSCs and 
describes FDA guidance that explicitly states the agency’s intention to 
 
2. All reference to ASCs or MSCs in this Article refer specifically to autolo-
gous ASCs that are used for non-homologous purposes. 
3. NIH Stem Cells Basics, NIH, http://stemcells.nih.gov/info/basics/basics1.asp 
(last updated Apr. 28, 2002).  
4. Mary A. Chirba & Stephanie Garfield, FDA Oversight of Autologous Stem 
Cell Therapies: Legitimate Regulation of Drugs and Devices or Groundless 
Interference with the Practice of Medicine, 7 J. HEALTH & BIOMED. L. 233, 
234 (2011). 
5. Id. at 235. 
6. See generally Phanette Gir et al., Human Adipose Stem Cells: Current 
Clinical Applications, 129 PLASTIC & RECONSTRUCTIVE SURGERY 1277 
(2012); Bettina Lindroos et al., The Potential of Adipose Stem Cells in  
Regenerative Medicine, 7 STEM CELL REVIEWS AND REPORTS 269 (2011). 
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regulate MSCs and adipose stem cells as somatic cell therapy products 
within the framework of biological products and drugs. Part III discusses 
the current scientific research examining potential clinical uses of ASCs 
and summarizes the numerous and potentially severe risks associated 
with autologous ASC injections for non-homologous use, where the 
injected stem cells are intended to differentiate and restore and repair 
other areas of the brain or body. Part IV provides an overview of 
Celltex’s business practices and product claims. It discusses concerns 
raised by bioethicists and the media and also describes the FDA’s recent 
findings during a facility inspection. Part V describes why Celltex’s 
business arrangement with RNL Bio raises additional concerns and 
summarizes allegations against the company’s subsidiary as set forth in a 
recent lawsuit connected to the subsidiary’s business practices in Los 
Angeles, California. Part VI summarizes recent litigation in which the 
FDA asserted its authority under the PHSA and the FDCA to regulate 
Regenerative Sciences’ practices of manufacturing and facilitating the 
injection of MSCs to patients. This non-binding precedent is significant 
because it affirms that the FDA has appropriately set forth regulations 
to classify types of ASCs and has the authority to regulate MSCs under 
the PHSA and the FDCA. Finally, Part VII explores the implications for 
physicians performing the injections and examines regulations set forth 
by the Texas Medical Board, professional standards, and Texas state 
law.  
I.  The Rise of ASCs in Texas: Dr. Stanley Jones, 
Gov. Rick Perry, Celltex Therapeutics, and RNL Bio 
In the past few years, both local and national media have reported 
on the development of initiatives to advance ASCs for treatment 
purposes in Texas. In May 2010, an orthopedic surgeon named Dr. 
Stanley Jones traveled with his wife, Kathi Jones, a registered nurse and 
owner of a medical spa, to Kyoto, Japan to undergo ASC infusions 
administered by RNL Bio, a company based in Seoul, South Korea.7 Five 
months later, the company reported in a press release that Dr. Jones 
experienced complete recovery from his autoimmune arthritis.8  
Jones, a personal friend of Texas Governor Rick Perry, stated that 
he felt compelled and “moved by his faith” to call on Perry for his 
 
7. Andrea Vasquez, Perry Watch: Perry’s Back Surgery Included  
Experimental Stem Cell Therapy, HOUS. CHRON.: TEXAS ON THE POTOMAC 
(Aug. 4, 2011), http://blog.chron.com/txpotomac/2011/08/perry-watch-
perrys-back-surgery-included-experimental-stem-cell-therapy. 
8. Id. For sake of clarity, references to RNL include RNL Bio and RNL Life 
Sciences (now Human Biostar).  
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support to permit commercializing ASC procedures in Texas.9 In 
addition to the close relationship between Jones and Perry, Celltex co-
founder David Eller contributed a substantial amount to Perry’s election 
campaign.10 In July 2011, Texas newspapers and online media outlets 
widely reported that Jones performed an infusion of autologous MSCs by 
injecting the cells into Perry’s back and bloodstream as a treatment for 
Perry’s existing back injury.11 Weeks after Perry received the injections, 
he contacted the Texas Medical Board (the Board) at Jones’ behest, 
requesting that it promulgate rules to ensure that physicians would be 
permitted to perform stem cell infusions.12 Around the same time, Texas 
State Representative Rick Hardcastle, who also received MSC infusions 
from Jones, sent a letter to the Board. A month prior to Perry’s injec-
tion in the summer of 2011, Rep. Hardcastle introduced legislation to 
create a stem cell bank in the state and wrote to the Board that he did 
not intend to create “onerous and unnecessary regulations to impede the 
practice and research of physicians in regards to the use of investigation-
al agents.”13 
The amount of publicity around Perry’s injections attracted the  
attention of Nature, which began publishing articles on the use of ASCs 
in Texas and FDA regulations relating to the practice. Perry continued 
to publicly acclaim his infusions and expressed his hope that “Texas 
[would] become the world’s leader in the research and use of adult stem 
cells” and “lead the nation in advancing adult-stem-cell research that 
will treat diseases, cure cancers, and ultimately, save lives.”14 Despite 
Perry’s claims, Nature reiterated that the FDA has not approved such 
ASC treatments because it regulates cells that undergo more than 
minimal manipulation during the cell culturing process.15 In the past few 
years, manufacturers and clinics in the United States have begun 
 
9. Emily Ramshaw, Perry’s Adult Stem Cell Treatment Was Doctor’s First 
Attempt, TEX. TRIB. (Aug. 4. 2011), http://www.texastribune.org/2011/ 
08/04/perrys-stem-cell-treatment-was-doctors-first-attem. 
10. Emily Ramshaw, Key Players Drive Texas Medical Board Stem Cell Rules, 
TEX. TRIB. (Feb. 9, 2012), http://www.texastribune.org/texas-health-
resources/texas-medical-board/key-players-drive-texas-medical-boards-
stem-cell-r. 
11. Id.; Emily Ramshaw, Perry, Allies Lay Groundwork for TX Stem Cell 
Industry, TEX. TRIB. (Aug, 4, 2011), http://www.texastribune.org/2011/ 
08/04/perry-allies-lay-groundwork-tx-stem-cell-industry. 
12. Letter from Rick Perry, Governor of Texas, to Irvin E. Zeitler, Jr., 
Chairman, Texas Medical Board (July 25, 2011), available at 
http://freepdfhosting.com/a30d34c191.pdf. 
13. Ramshaw, supra note 10; David Cyranoski, Texas Prepares to Fight for 
Stem Cells, 477 NATURE 377, 378 (2011). 
14. Cyranoski, supra note 13, at 377. 
15. Id. at 378. 
Health Matrix·Volume 23·Issue 2·2013  
Challenging the FDA’s Authority to Regulate Autologous Adult Stem Cells 
498 
circumventing FDA regulations in various ways: by sending patients 
overseas for the injections (RNL Bio and RNL Life Sciences); asserting 
that the manufacture and injection of ASCs falls within the practice of 
medicine (Regenerative Sciences and Stanley Jones); or arguing that 
MSCs do not fall within the regulatory definition of “drugs” overseen by 
the FDA (Regenerative Science and Celltex).16 Specifically, manufacturers 
such as Celltex argue that the process of culturing and preparing the 
stem cells does not constitute the manufacture of a biological drug, so 
the process stands outside the scope of FDA’s regulatory authority.17 
In December 2011, Celltex opened its doors for business to manufac-
ture and facilitate the process for individuals seeking to receive stem cell 
injections.18 Founded by Jones and Eller, Celltex uses technology 
licensed from RNL Bio to process stem cells.19 Several months later, 
Nature published another article describing Celltex’s company practices, 
whereby Celltex coordinates with local physicians to remove a patient’s 
adipose tissue that Celltex then processes, cultures, and expands to 
produce mesenchymal stem cells over a period of three weeks.20 Celltex 
charges patients an estimated twenty to thirty thousand dollars for 
monthly MSC injections, of which coordinating physicians receive five 
hundred dollars per injection.21 One Houston-based physician, Dr. 
Jamshid Lofti, has worked with Celltex to administer ASC injections 
manufactured by Celltex to more than twenty people for diseases such as 
multiple sclerosis and Parkinson’s disease.22 According to Lofti, patients 
generally receive three injections over several months. 23 He claims that 
most of his patients report improvement, although he acknowledges the 
limitations of anecdotal evidence in medicine.24  
 
16. Id. 
17. Id. 
18. David Cyranoski, Stem-Cell Therapy Takes Off in Texas, 483 NATURE 13, 
13 (2012). 
19. Id. 
20. Leigh Turner, Celltex Makes Bold Marketing Claims Despite Significant 
Manufacturing Problems Found During FDA Inspection, HEALTH IN THE GLOBAL 
VILLAGE (Aug. 7, 2012), http://www.healthintheglobalvillage.com/2012/08/ 
07/Celltex-makes-bold-marketing-claims-despite-significant-manufacturing-
problems-found-during-fda-inspection. 
21. Cyranoski, supra note 18, at 14. According to Lofti’s information, if Celltex 
pays him $500 per injection, patients generally receive at least three  
injections, and he has “treated” more than 20 patients, Celltex has paid 
Lofti at least $30,000 from December 2011 to March 2012. 
22. Id. at 13. 
23. See id.  
24. Id. at 14. 
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Problematically, Lofti and Jones have dismissed any risks arising 
from undergoing MSC injections.25 Lofti echoed Perry’s praise of ASCs, 
asserting that they could be “a panacea, from cosmetics to cancer” and 
that “the worst case scenario is that [the ASC treatment] won’t work.”26 
Similarly, months before Celltex opened, when Jones discussed Perry’s 
injections with the media, Jones claimed that ASC injections had “no 
side effects” and that pharmaceutical drugs posed more risks to patients. 
He did acknowledge, however, that ASCs might not work for everyone.27 
Scientific literature in this area not only demonstrates the presence of 
risks potentially arising from using ASCs in clinical therapy but also 
shows the severity and nature of those risks, including transmitting 
viruses or endotoxins, inducing a potentially fatal immune reaction, 
creating tumors within the body, and differentiating inappropriately and 
leading to pulmonary emboli or myocardial infarctions.28 Jones’ state-
ments are especially worrisome because he is both a co-founder of Celltex 
and has administered injections to at least two patients (Perry and 
Hardcastle). Accordingly, it is uncertain whether and how he discussed 
the risks of the procedure with his patients. There are questions of how 
accurately Celltex represents risks to patients in general. 
Bioethicists, scientists, and the FDA responded to emerging infor-
mation of Celltex’s business practices, the promises of ASCs’ potential, 
and the disclosure of potential risks. George Daley, the Director of the 
Stem Cell Transplantation Program at Harvard Medical School, has 
explained the experimental nature of any treatment and how little the 
scientific community knows about ASCs.29 He affirmed that patients who 
receive MSC injections are indeed exposed to risks from the cells, the 
conditions of their manufacture, and the procedure itself.30 Furthermore, 
Daley and other stem cell scientists questioned why Celltex was charging 
patients substantial sums of money for procedures it could not prove 
were effective through FDA-regulated clinical trials.31 Bioethicist Leigh 
Turner took note and began authoring meticulous media updates on 
company practices and wrote a letter to the FDA thoroughly detailing 
numerous legal and ethical concerns.32 Rita Chappelle, a spokesperson for 
 
25. See id.; Ramshaw, supra note 9. 
26. Cyranoski, supra note 18, at 14. 
27. Ramshaw, supra note 9. 
28. See infra Part IV.  
29. Cyranoski, supra note 18, at 14. 
30. Id. 
31. Id. 
32. Letter from Professor Leigh Turner, Univ. of Minn. Ctr. for Bioethics, to 
Dr. Karen Midthun, Director, Ctr. for Biologics Evaluation and Res., Food 
and Drug Admin. (Feb. 21, 2012), available at http://freepdfhosting.com/ 
46b331a006.pdf [hereinafter “Turner Letter”]. 
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the FDA’s Center for Biologics Evaluation and Research, affirmed that if 
a manufacturer processes the cells for expansion, this constitutes more 
than “minimal manipulation” and would subject the manufacturer to 
FDA regulation.33 A former reviewer at the Center alleged that “if Perry 
was treated in the United States, it was clearly in violation of FDA 
regulation.”34 
II.  FDA Regulation of ASCs 
A.  Regulation of Human Cell and Tissue Products (HCT/Ps) 
Under the Public Health Service Act (PHSA), the FDA regulates 
human cell and tissue products (HCT/Ps), which refers to articles 
“containing or consisting of human cells or tissues that are intended for 
implantation, transplantation, infusion, or transfer into a human 
recipient.”35 According to the FDA, the goal of the regulations is 
“to improve protection of the public health without imposing unneces-
sary restrictions on research, development, or the availability of new 
products.”36 These regulations are designed to prevent contamination 
and communicable disease37 rather than to ensure safety and efficacy. 
They impose several requirements such as registering the HCT/Ps with 
the FDA and promulgating standards for Good Tissue Practice, includ-
ing monitoring the procedures, facilities, processing equipment, and 
supplies and reagents used in the manufacturing process.38 Under the 
HCT/P system Section 1271, the FDA classifies different types of human 
cells, tissues, and cellular and tissue-based products into categories for 
regulation based on the public health risks they pose: (1) products not 
subject to HCT/P regulations, (2) HCT/Ps regulated under Section 361 
of the PHSA, and (3) products posing the most risk that are to be 
regulated stringently as a biological product or drug.39  
In 2006, the FDA replaced a single word in its definition of HCT/Ps, 
substantially changing its official application.40 Previously, the regulation 
defined HCT/Ps as “articles containing or consisting of human cells or 
 
33. Cyranoski, supra note 18, at 14. 
34. Cyranoski, supra note 13, at 378. 
35. 21 C.F.R. § 1271.3(d) (2012). 
36. Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 Fed. 
Reg. 5447 (Jan. 19, 2001) (codified at 21 C.F.R pts. 207, 807, & 1271). 
37. See 21 C.F.R. § 1271.145 (2012); Barbara von Tigerstrom, The Food and 
Drug Administration, Regenerative Sciences, and the Regulation of  
Autologous Stem Cell Therapies, 66 FOOD & DRUG L.J. 479, 485 (2011). 
38. 21 C.F.R. § 1271.150 (2012). 
39. Id. §§ 1271.1, 1271.150; Chirba & Garfield, supra note 4, at 250. 
40. 21 C.F.R. § 1271.3(d) (2012) (changing the phrase “another human recipient” 
to “a human recipient”); Chirba & Garfield, supra note 4, at 253. 
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tissues that are intended for implantation, transplantation, infusion, or 
transfer into another human recipient.”41 The FDA replaced the word 
“another” with “a,” which formally included autologous products within 
the classification of HCT/Ps.42 Scholars have debated this agency action, 
arguing that the FDA failed to provide the sufficient notice and com-
ment generally required for rulemaking. Others maintain that the FDA 
repeatedly announced its intention to regulate both allogenic (stem cells 
derived from one individual and used in a different individual) and 
autologous therapies (stem cells derived from one individual and used in 
that same individual) in previous guidance documents, and therefore this 
change merely updated the regulations to reflect the new HCT/P risk 
classification system.43 However, manufacturers such as Regenerative 
Sciences have recently used this particular modification as a basis to 
challenge the FDA’s authority to regulate ASCs even under the less 
onerous HCT/P framework.44 The FDA has since stated this change 
merely represented an interpretative rule to clarify existing regulations 
and constituted a procedural rather than substantive change, and 
therefore the agency did not need to abide by notice and comment 
procedures.45  
The first category in Section 1271 lists products that the FDA does 
not regard as human cell- or tissue-based products subject to this 
regulation, such as human organs for transplantation, whole blood, and 
bone marrow.46 Section 1271 states that the FDA does not consider a 
product to be an HCT/P under the regulation if the product is only 
“minimally manipulated” and is intended for homologous use. In other 
words, a product is not subject to the regulations set forth in the 
HCT/P system if the manufacturing and processing of the cells does not 
alter the cells’ relevant biological characteristics and the cells will serve 
the same biological function in the donor and recipient.47 
Section 361 of the PHSA provides the FDA with authority to regu-
late the second category of products in the HCT/P system. The FDA 
will not regulate the HCT/P solely under Section 361, subjecting any of 
the following circumstances to more stringent regulation as a drug or 
biologic: (1) if the manufacturing and processing alters the relevant 
biological characteristics of the cells; (2) if the cells are intended to serve 
a different biological function after transfer to the recipient; or (3) if the 
 
41. See Chirba & Garfield, supra note 4, at 253–54. 
42. Id. at 254. 
43. Id.; von Tigerstrom, supra note 37, at 488–89. 
44. See infra Part VII. 
45. Chirba & Garfield, supra note 4, at 266–67. 
46. 21 C.F.R. § 1271.3 (2012); Chirba & Garfield, supra note 4, at 250; von 
Tigerstrom, supra note 37, at 485. 
47. von Tigerstrom, supra note 37, at 485. 
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manufacture of the HCT/P involves the combination of the cells with 
another article that is not an agent intended to sterilize, preserve, or 
store.48  
B.  Regulation under the PHSA and the FDCA 
If the product does not meet all the requirements set forth in Section 
1271, the FDA will regulate it as a “biological product” under Section 
351 of the PHSA or as a “drug” under the FDCA, which requires stricter 
regulation than a Section 361 product.49 Under the FDCA, a manufac-
turer must show its drug is both “safe” and “effective” prior to moving 
the drug in interstate commerce.50  
A “biological product” is defined as “a virus, therapeutic serum, toxin, 
antitoxin, vaccine, blood, blood component or derivative . . . or analogous 
product . . . applicable to the prevention, treatment, or cure of a disease 
or condition of human beings.”51 A biological product manufacturer must 
(1) obtain a biologics license to deliver the product into interstate  
commerce; (2) demonstrate to the FDA that the product is safe, pure, and 
potent; (3) abide by contemporary good manufacturing practices 
(cGMPs); and (4) submit post-market studies and clinical trial  
information.52 
Under the FDCA, a “drug” refers to an article that is “intended for 
use in the diagnosis, cure, mitigation, or prevention of disease,” or an 
article that is “intended to affect the structure or any function of the body 
of man or other animals.”53 The intended use refers to the manufacturer’s 
objective intent, which can be determined from labeling claims, advertise-
ments, or written or oral statements by the manufacturer or its 
representatives.54 Jurisprudence in this area has held that the definition 
of the word “drug” should be read as widely as possible and that its 
scope should not be limited to products commonly referred to as drugs.55 
Once the FDA determines that a product is a drug, the manufacturer is 
 
48. See Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 
Fed. Reg. 5447 (Jan. 19, 2001) (codified at 21 C.F.R pt. 207, 807, & 1271). 
49. See Suzan Onel et al., Cultured Stem Cells for Autologous Use: Practice of 
Medicine or FDA Regulated Drug and Biological Product?, K & L GATES 1 
(Sept. 19, 2011), http://www.klgates.com/files/Publication/93fd6a2d-ef3a-
4259-b20a-8abb1d1ffbce/Presentation/PublicationAttachment/4fe18eca-fa06-
465c-a52f-8e4cf7ddb80e/FDA_Alert_Cultured_Stems_Cells_ 091911.pdf. 
50. See Chirba & Garfield, supra note 4, at 243. 
51. 42 U.S.C. § 262(h)(i) (2012). 
52. Id. § 262(a). 
53. 221 C.F.R. § 201.128 (2012); von Tigerstrom, supra note 37, at 484 
(quoting 21 U.S.C. §§ 321(g)(1)(B), 321(g)(1)(C) (2006)); Chirba &  
Garfield, supra note 4, at 245. 
54. 221 C.F.R. § 201.128; Chirba & Garfield, supra note 4, at 245. 
55. Chirba & Garfield, supra note 4, at 246. 
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subject to the FDA’s pre-marketing requirements designed to ensure the 
drug’s safety and efficacy, which includes submitting a new drug 
application or an investigational new drug application (IND), undergoing 
investigational drug studies approved by an institutional review board 
(IRB), complying with cGMPs, and conducting clinical trials.56 
C.  FDA Guidance and Application to ASCs 
In the 1990s, the FDA promulgated guidance that classified MSCs 
and adipose stem cells as somatic cell therapy products (autologous, 
allogeneic, or xenogeneic living cells, which have been manipulated, 
processed, or expanded) and excluded them from the list of HCT/Ps 
that the FDA intended to regulate solely under Section 361.57 During its 
revision of the regulations pertaining to HCT/Ps in 2001, the FDA 
stated in its rulemaking preamble that the agency did “not agree that 
the expansion of mesenchymal cells in culture . . . [is] minimal manipula-
tion,” announcing that it intended to regulate such ASCs within the 
framework of biological products and drugs.58 Indeed, guidance on the 
FDA’s website clarifies that “human somatic cell therapy products 
include autologous or allogeneic cells that have been propagated, 
expanded, pharmacologically treated, or otherwise altered in biological 
characteristics ex vivo to be administered to humans and applicable to 
the prevention, treatment, cure, diagnosis, or mitigation of disease or 
injuries” and are subject to regulation as a biological product and or 
drug.59 In January 2012, the FDA issued a Consumer Health Information 
Guide, cautioning consumers to make sure that any stem cell treatment 
they consider has been approved by the FDA or is subject to a current 
protocol submitted to the FDA to ensure that the stem cells are safe, 
effective, and have undergone adequate and well-controlled clinical 
 
56. Id. at 247, 252; Onel et al., supra note 49. 
57. GUIDANCE FOR HUMAN SOMATIC CELL THERAPY AND GENE THERAPY 7–8 
(1998), available at http://www.fda.gov/downloads/BiologicsBloodVaccines/ 
GuidanceComplianceRegulatoryInformation/Guidances/CellularandGene 
Therapy/ucm081670.pdf; REGULATION OF HUMAN CELLS, TISSUES, AND 
CELLULAR AND TISSUE-BASED PRODUCTS (HCT/PS), SMALL ENTITY 
COMPLIANCE GUIDE 4 (2007), available at http://www.fda.gov/downloads/  
BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ 
Tissue/ucm062592.pdf; Revised Instructions for Listing Other HCT/Ps on 
Form 3356 or in eHCTERS, FDA, http://www.fda.gov/BiologicsBlood 
Vaccines/GuidanceComplianceRegulatoryInformation/Establishment 
Registration/TissueEstablishmentRegistration/ucm146772.htm (last updated 
May 5, 2009). 
58. Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 Fed. 
Reg. 5,447, 5,457 (Jan. 19, 2001) (codified at 21 C.F.R pts. 207, 807, 1271). 
59. Revised Instructions, supra note 57. 
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trials.60 Accordingly, the FDA must also oversee the manufacturing 
process to assure the products’ safety, purity, and potency.61  
Despite the FDA’s clarity that MSCs constitute biological products 
and drugs, some manufacturers have attempted to challenge the FDA’s 
interpretation of the enabling statutes in the PHSA and the FDCA.62 
Two companies—Regenerative Sciences and Celltex—have recently 
challenged the FDA’s regulation of ASCs as biological products and 
drugs.63 These challenges are especially worrisome based on the emerging 
science of ASCs, uncertainties about their safety and efficacy, and the 
inherent risks posed by ASC injections.  
III.  Risks of ASCs in Scientific Literature 
Scientific literature discussing the clinical applications of ASCs for 
regenerative medicine lends support to the FDA’s position that expand-
ing and processing the cells constitutes more than minimal manipulation 
and that the FDA must regulate ASCs as biological products and drugs. 
Literature reviews note that we are in the process of developing an 
understanding of the safety and efficacy of using ASCs.64 Scientists have 
only begun to conduct clinical trials in the past few years, and the 
published data that is currently available often originates from uncon-
trolled studies or studies monitoring only a limited number of patient 
outcomes.65 As of August 2012, only seventy autologous adipose stem cell 
therapy studies have been or are currently in the process of being 
conducted in human trials worldwide.66 These studies examine the use of 
MSCs derived from adipose cells to treat diseases ranging from conges-
tive heart failure to multiple sclerosis to autism.67 Notably, most of the 
discussions regarding regulatory considerations presume that ASCs for 
 
60. FDA Warns About Stem Cell Claims, FDA, http://www.fda.gov/downloads/ 
ForConsumers/ConsumerUpdates/UCM286213.pdf. 
61. Id. 
62. Chirba & Garfield, supra note 4, at 257; von Tigerstrom, supra note 37, at 
482-86. 
63. Regenerative Sciences sets forth additional arguments that are outside the 
scope of this Article. See Celltex Responds to Media Reporting in FDA Visit: 
Company Pioneering Regenerative Medicine Services Invited FDA to Inspect 
Lab, CELLTEX THERAPEUTICS (June 27, 2012), http://www.celltexbank.com/ 
Celltex-responds-to-fda-visit/ (last visited Sept. 1, 2012); von Tigerstrom, 
supra note 37, at 485–86.  
64. Gir et al., supra note 6, at 1279; Lindroos et al., supra note 6, at 269. 
65. Id. at 270. 
66. A search for the term “adipose stem cell therapy” on the NIH Clinical 
Trials website in August 2012 yielded seventy studies. Basic Search, 
CLINICAL TRIALS, http://www.clinicaltrials.gov/ct2/search. 
67. See id. 
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use in clinical therapies are subject to FDA regulation as a biological 
product and drug and would require the manufacturer to comply with 
GMPs, file appropriate forms, and conduct clinical trials.68  
Clinicians can obtain adipose (fat) tissue from liposuction aspirates, 
and scientists next isolate and extract the ASCs and then apply induc-
tion factors including chemicals and growth serum to expand the ASCs 
in culture medium over a period of several weeks.69 Both the culture 
medium and the choice of growth serum affect how the cells grow and 
differentiate as well as the overall health and quality of the cells.70 
Processing the ASCs in growth serum enables their survival and offers 
the cells protection from cytotoxic agents.71 Because fetal bovine growth 
serum (FBS) is rich in growth factors and stimulates protein secretion in 
the cells during their proliferation,72 most studies have used FBS as the 
choice of growth agent. The FDA has approved MSCs cultured using 
FBS for clinical trials in the United States during Phase I trials, but 
some regulatory agencies would require xeno-free or serum-free media 
during later phase studies or in the application of clinical therapy.73  
The process of expanding and culturing stem cells can change the 
biological characteristics of the ASCs.74 That is, each division of the cell 
creates the possibility of problematic mutations, and the mechanisms 
that ordinarily correct these changes may not function adequately during 
the in vitro process.75 Accordingly, this observation means that ASCs 
cannot be treated as minimally manipulated and cannot be regulated 
solely under Section 361.76 Research has also demonstrated the increasing 
genetic instability of cells connected to the amount of time left in 
culture, showing that too much time expanding in culture can alter the 
genetic composition of cells.77 Scientific literature has concluded that this 
particular risk warrants extensive pre-clinical studies to determine safety 
and efficacy and subsequently recommends monitoring the genetic 
 
68. See Gir et al., supra note 6, at 1280. 
69. Lindroos et al., supra note 6, at 273, 275–77. 
70. Id. at 275, 277; see Carla Herberts et al., Risk Factors in the Development of 
Stem Cell Therapy, J. TRANSLATIONAL MED., Mar. 2011, at 1, 6; Chandana 
Tekkatte et al., “Humanized” Stem Cell Techniques: The Animal Serum 
Controversy, 2011 STEM CELLS INT’L [doi: 10.4061/2011/504723 at 3] (2011).  
71. Tekkatte et al., supra note 6 at 3.  
72. Lindroos et al., supra note 6, at 279. 
73. Lindroos et al., supra note 6, at 279, 284; Tekkatte et al., supra note 70 at 
3, 10.  
74. Herberts et al., supra note 70, at 6. 
75. Id.  
76. See 21 C.F.R. § 1271.3(f) (2012). 
77. Lindroos et al., supra note 6, at 284. 
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stability of cells during the manufacturing process and following injec-
tion.78  
In addition to the intrinsic risks involved in the expansion process, 
the choice of growth serum and other adventitious agents both influences 
the cells’ ability to proliferate and poses additional risks.79 Human cells 
that are exposed to xenogenic products (foreign substances) originating 
from cell culture reagents may transfer xenogenic antibodies into the 
recipient once the cells are injected.80 Literature has widely acknowl-
edged risks specifically from using FBS, such as activating immune 
responses, with reports of anaphylactic shock or Arthus-like immune 
reactions in patients following introduction of cells grown in FBS 
media.81 FBS also poses the risk of transferring numerous viruses, 
bacterial infections, prions, and even currently unidentified zoonoses 
(cross-species diseases).82 Additionally, the serum could potentially 
become contaminated with yeast, fungi, and endotoxins, some of which 
are impossible to remove from the serum.83 Although processing can 
remove most of the FBS prior to clinical use, trace bovine proteins may 
remain sufficient to trigger an immune response and some contaminants 
(such as viruses, prions, and nanobacteria) are impossible to remove.84 
Notably, Jeong Chan Ra of RNL Bio has published on the safety 
and potential risks of MSCs for therapeutic human use using FBS as a 
growth factor.85 Ra’s article asserts that RNL’s methodology “completely 
removed” FBS from cultured MSCs.86 These specific methodology and 
research claims are critical because Celltex advertises numerous claims 
on its website relating to the company’s use of RNL Bio’s methods for 
processing the ASCs it facilitates for patient injection.87 Celltex does not 
advertise its specific methods for ASC expansion or clarify on its website 
material its choice of growth serum.  
 
78. Id.  
79. Tekkatte et al., supra note 70, at 10. 
80. Lindroos et al., supra note 5 at 279. 
81. Tekkatte et al., supra note 70, at 3. 
82. Lindroos et al., supra note 6, at 279. 
83. Tekkatte et al., supra note 70, at 2. 
84. Id. at 2, 10. 
85. Jeong Chan Ra et al., Safety of Intravenous Infusion of Human Adipose 
Tissue-Derived Mesenchymal Stem Cells in Animals and Human, 20 STEM 
CELLS & DEV. 1297, 1306 (2011). 
86. Id. at 1298. 
87. See Tekkatte et al., supra note 70, at 4–8; Sven Kinzebach & Karen 
Bieback, Expansion of Mesenchymal Stem/Stromal Cells under Xenogenic-
Free Culture Conditions, 129 ADVANCES IN BIOCHEMICAL 
ENG’G/BIOTECHNOLOGY 33 (2013). 
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Based on the risks described above, scientists have begun to examine 
the possibility of using either xeno-free serum or serum-free culture 
conditions.88 However, such xeno-free and culture-free media have not 
yet been shown to be safe or effective.89 Some scientists in this area have 
proposed creating autologous serum derived from the intended patient, 
but studies have not been able to confirm cells’ ability to differentiate, 
proliferate, or show consistent growth in autologous serum.90 As  
discussed above, too much time in culture can create genetic instability 
in the cells, so the culture formula must be able to expand the cells 
within this anticipated maximum in vitro time period.91 Recent studies 
have also suggested that autologous serum may not serve as an effective 
medium when it is derived from older individuals because preliminary 
studies have shown it interferes with MSCs capacity to proliferate and 
differentiate.92 Furthermore, autologous serum derived from human blood 
poses additional risks that would require further investigation prior to 
human clinical application.93 
ASCs also pose a number of clinical risks related to tumor growth 
once the ASCs are injected. Inherent properties of stem cells are similar 
to cancer cells: they have a long life span, they are resistant and can 
replicate over extended periods of time, and they are controlled by 
similar growth regulators within the body.94 Scientific literature widely 
cites the risk of tumor formation as one of the most difficult obstacles to 
using ASCs in clinical therapies.95 If cells are kept too long in culture 
and undergo chromosomal alterations, some studies have found this 
increases their risk of tumorigenicity.96 Injection of ASCs also poses the 
risk of bystander tumor formation where the injected cells can affect the 
growth of existing previously undetected tumor cells within the body.97  
The literature recognizes several other distinct concerns that pose a 
risk to clinical use of ASCs. Scientists still do not fully understand the 
 
88. Francisco dos Santos et al., Toward A Clinical-Grade Expansion of 
Mesenchymal Stem Cells From Human Sources: A MicroCarrier-Based 
Culture System Under Xeno-Free Conditions, 17 TISSUE ENG’G PART C: 
METHODS 1201 (2011); Tekkatte et al., supra note 70, at 3, 10. 
89. See generally Kinzebach & Bieback, supra note 84; Tekkatte et al., supra 
note 70, at 4–8. 
90. Tekkatte et al., supra note 70, at 4–8; Lindroos et al., supra note 6, at 280. 
91. Lindroos et al., supra note 6, at 280. 
92. Herberts et al., supra note 70, at 8–9. 
93. Tekkatte et al., supra note 70, at 4–8 
94. Herberts et al., supra note 70, at 4–5. 
95. Id. at 6; Gir et al., supra note 6, at 1279. 
96. Herberts et al., supra note 70, at 6. 
97. Id. at 7.  
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mechanism that controls ASCs’ migration, but research shows that the 
migration of cells to particular parts of the body could influence their 
biological properties and growth, and the risks that unengrafted cells 
pose to the recipient cells are unknown.98 It is also generally unknown 
how many cells are needed for clinical benefit, which poses the dilemma 
of choosing how many cells to administer during the injection. If the 
injection contains too few cells, it may lack efficacy, but if it contains 
too many cells, they may migrate inappropriately throughout the body 
or form cell aggregates that could cause pulmonary emboli or infarc-
tions.99 Animal models have shown that injected MSCs could also 
differentiate into unwanted cell types such as osteocytes and adipocytes, 
which can cause calcification or ossification in the heart potentially 
leading to a myocardial infarction.100 
The manufacturing process and methods can pose extrinsic additional 
risks if the final product injected into the patient has been contaminated 
or lacks purity. Literature in this area describes in detail each of the 
cGMPs manufacturers must follow, such as quality controls, processing 
controls, and cell viability and phenotype testing.101 The manufacturer 
must closely monitor the processing to ensure that the cells have not 
inappropriately proliferated and changed genetic structure and that the 
cells have expanded sufficiently to yield the appropriate number of 
expanded cells.102 Close oversight of environmental controls, equipment 
monitoring, and checking supplies and reagents is necessary to prevent 
contamination and ensure that the final product is safe for use and that 
it has the appropriate ingredients and potency.103 Failing to adhere to 
cGMPs means that the product may not only lack the characteristics it 
claims to have—genetically similar sufficient amount of ASCs—but it 
may also contain genetically mutated cells or inappropriate adventitious 
agents or pose a threat of contamination from bacteria or viruses.104 
The risks discussed above relate not only to potential contamination 
or inadequate processing but also stem from the intrinsic and clinical 
characteristics of using ASCs, which requires extensive studies examining 
safety and efficacy to mitigate potential risks in clinical application. The 
amount and severity of these risks, as well as the lack of knowledge of 
how to control their occurrence, lends support to the FDA’s classifica-
 
98. See id. at 9.  
99. See id. 
100. Id. 
101. Lindroos et al., supra note 6, at 279. 
102. Id.  
103. See Drug Applications and Current Good Manufacturing Practice (cGMP) 
Regulations, FDA, http://www.fda.gov/Drugs/DevelopmentApproval  
Process/Manufacturing/ucm090016.htm (last updated Sept. 7, 2012).  
104. See Lindroos et al., supra note 6, at 279; Herberts et al., supra note 70, at 8. 
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tion of MSCs as biological products and drugs. That is, even under the 
most carefully controlled manufacturing process, MSCs pose a number of 
significant risks including transmitting viruses or endotoxins, inducing a 
potentially fatal immune reaction, creating tumors within the body, and 
differentiating inappropriately, which could lead to pulmonary emboli or 
myocardial infarctions. Should a manufacturer fail to closely monitor 
and regulate the manufacturing process, the injection of MSCs poses 
additional and entirely distinct risk factors and potential complications 
to the recipient.  
IV. Celltex Therapeutics  
A. Red Flag: Professor Turner’s Letter to the FDA 
The existence of these risks as well as the minimization or denial of 
such risks in the media by Celltex raises serious concerns about business 
practices that expose patients to potentially serious harm. For the first 
several months of operation, Celltex’s company practices, including 
statements by Jones, were reported through media accounts, and the 
company’s policies and procedures were publicly unknown. But these key 
pieces of information were clear: Governor Perry openly advocated for 
the procedure; Jones minimized and outright denied its risks; physicians 
such as Jones (and later Lofti) reported that they performed injections; 
the FDA unambiguously classified MSCs as biological drugs; and 
scientific literature explained the significant risks posed by the proce-
dure. Bioethics media such as the Center for Genetics and Society took 
note and began reporting on and questioning the implications of “emerg-
ing science commercialized as medicine” and positing questions about 
Celltex’s informed consent process based on Jones and Lofti’s comments 
to the media.105 Prior to the public knowledge that Lofti performed 
additional procedures, bioethicist Professor Leigh Turner began a 
campaign to investigate Celltex’s practices.106 In February 2012, Turner 
sent a lengthy and detailed letter to the Director of the Center of 
Biologics Evaluation and Research at the FDA enumerating eight 
specific concerns about Celltex’s practices, such as the lack of evidence 
to demonstrate the safety or efficacy of injections Celltex was adminis-
tering, Celltex’s relationship with RNL Bio, allegations that RNL Bio’s 
injections caused deaths in Korea, and concerns relating to informed 
consent.107  
 
105. Pete Shanks, Stem Cell Fraud Is the Real Issue In Texas, BIOPOLITICAL 
TIMES (Mar. 2, 2012), http://www.biopoliticaltimes.org/article.php? 
id=6099; Pete Shanks, Rick Perry, Glenn McGee and Selling Texas Stem 
Cells, BIOPOLITICAL TIMES (Feb. 16, 2012), http://www.biopolitical 
times.org/article.php?id=6078. 
106. Turner Letter, supra note 32. 
107. Id. 
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Celltex responded with a letter from its legal counsel asserting 
Turner’s “allegations” in the letter to the FDA were false.108 The letter 
further maintained that Celltex “is duly registered with the FDA as a 
Section 361 facility” because it is a lab that merely “processes stem cells 
at the behest of independent physicians who diagnose and prescribe to 
their patients.”109 Lastly, the letter assured the FDA that “Celltex’s 
process ensures that cells are genetically identical to the original and free 
from any contaminants.”110 This short letter set forth strong claims. 
First, despite its method of processing the MSCs using twelve supplies 
and reagents over a period of weeks, Celltex considers its product to fall 
within Section 361 regulation involving no more than minimal manipula-
tion and entailing minimal risk. Celltex did not address how it satisfies 
the additional criteria requiring that the product will be used in a 
homologous manner, which is also required for the FDA to regulate it as 
a Section 361 product. Second, it asserted that Celltex’s manufacturing 
procedures are so meticulous and advanced as to promise what the 
scientific literature has considered a serious obstacle—ensuring enough 
time in culture and choosing effective adventitious agents for sufficient 
expansion but stopping proliferation prior to chromosomal deviations. 
 
B. FDA Inspection of Celltex  
In April 2012, the FDA performed a facility inspection of the Celltex 
lab over a period of two days. Turner and reporters at The Houston 
Chronicle sought public release of the inspection report through the 
Freedom of Information Act.111 The FDA’s 483 report112 made news 
headlines based on the number of deficiencies in Celltex’s processing and 
manufacturing procedures.113 Among the seventy-nine violations, the 
 
108. Letter from Jonathan Emord & Andrea Ferrenz, Emord & Associates, PC, 
to Dr. Karen Midthun, Dir., Center for Biologics Evaluation and Research, 
FDA (Mar. 9, 2012), available at http://www.circare.org/info/stemcell/ 
emord_fda_20120309.pdf. 
109. Id. 
110. Id. 
111. Todd Ackerman, FDA Report Faults Houston Stem-Cell Company, HOUS. 
CHRON., June 25, 2012, http://www.chron.com/news/houston-
texas/article/FDA-report-faults-Houston-stem-cell-company-3661778.php. 
112. See Inspection Observations, FDA, http://www.fda.gov/iceci/Enforcement 
Actions/ucm250720.htm (last updated Nov. 16, 2012) (“During an inspec-
tion, [Office of Regulatory Affairs] investigators may observe conditions 
they deem to be objectionable. These observations, are listed on an FDA 
Form 483 when, in an investigator’s judgment, the observed conditions or 
practices indicate that an FDA-regulated product may be in violation of 
FDA’s requirements.”). 
113. Ackerman, supra note 111; David Cyranoski, US Drug Regulator Audits 
Texas Stem Cell Company, NATURE NEWS BLOG (June 26, 2012), 
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report found that Celltex failed to validate processes to prevent contam-
ination, to distinguish between components being quarantined or 
approved, to routinely calibrate and check the equipment, and to review 
quality processing systems.114 The company could not guarantee the 
sterility, uniformity, viability, or integrity of the cells.115 Thus, according 
the inspection report, at best Celltex’s manufacturing process could not 
guarantee that the cells would actually expand and be viable upon 
injection, and at worst, the cells prepared for injection could be contam-
inated. As discussed above, even if a laboratory exactingly controls the 
manufacturing process during the expansion of MSCs, injecting MSCs 
poses significant risks to patients. Failure to comply with cGMPs 
exponentially increases the otherwise avoidable risks to the patient from 
injecting contaminated or unsterile cells.116 Perhaps most significantly, 
the inspection report classified Celltex as a biological drug manufacturer, 
which means the FDA classifies Celltex’s laboratory process of expand-
ing MSCs within the biological products and drug framework.  
Celltex responded by claiming that the company invited the FDA to 
view how it is “pioneering” regenerative medicine services.117 Celltex 
maintains that the investigation was a routine one to check that its 
practices were in accordance with the good tissue practices governing 
Section 361 products.118 Celltex’s first public response explained that the 
FDA’s “observations” arose from a language barrier because the  
scientists and technicians working in the laboratory licensed through 
RNL Bio speak and document their work in Korean.119 Language barrier 
aside, Celltex assured the public that it processes stem cells in a sterile 
laboratory according to procedures to guarantee the cells’ sterility, 
viability, and integrity.120 Notably, even after the inspection report 
classified Celltex as a biological drug manufacturer, Celltex staunchly 
held the position in press releases that it is solely an HCT/P manufacturer 
regulated under Section 361.121 Celltex added: “Some media reports and 
 
http://blogs.nature.com/news/2012/06/fda-hammers-texan-stem-cell-
company.html. 
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116. Ed Silverman, FDA Slams Stem Cell Company for Violation, 
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social media chatter suggest that Celltex is somehow acting illegally or 
providing unapproved treatments. These statements are inaccurate . . . 
Celltex’s process for reproducing adult mesenchymal stem cells is legal, 
and there is no requirement that the cells be approved or licensed.”122 
These statements not only ignored the deficiencies catalogued in the 
inspection report, but managed to directly challenge FDA regulatory 
definitions and guidance that clearly categorize expanded MSCs within the 
biological product and drug framework because they are more than 
minimally manipulated and intended for non-homologous use in patients. 
C. Celltex Prepares to Challenge the FDA 
Celltex’s website was under construction until the summer of 2012, 
limiting the amount of information available to the public about the 
company’s practices. Once Celltex operationalized its web presence, the 
company advanced several more claims relating to product safety and 
the company’s research integrity, regulatory and legal compliance, 
technological leadership, and innovation in providing ASCs for therapeutic 
use.123 Celltex’s website contains the same press release that had been 
issued publicly after the FDA’s inspection became public and continues 
to assert that the company is merely an HCT/P manufacturer regulated 
under Section 361. 
Celltex claims that scientists have researched this field extensively 
and that ASCs have been used safely and successfully for over fifty 
years, arguing dozens of studies have demonstrated their safety.124 
Numerous literature reviews in the field of ASC research in fact find the 
opposite: there are a lack of published results demonstrating successful 
clinical applications of ASCs for therapy; clinical potential is uncertain; 
known risks are significant and potentially severe; and the limited 
clinical trials available have shown serious adverse events in some cases, 
which means more knowledge is needed to understand the biological 
mechanisms of ASCs and their long term safety.125 Celltex’s website does 
not address these points of general consensus in the literature but offers 
a link to a study published by Jeong Chan Ra of RNL Bio and his 
colleagues that discusses the safety of MSCs for therapeutic use.126 The 
authors acknowledge the study’s limitations, concluding that the small 
 
122. Id. 
123. CELLTEX THERAPEUTICS, http://www.celltexbank.com/ (last visited Sept. 
1, 2013). 
124. Company Overview, CELLTEX THERAPEUTICS, http://celltexbank.com/about/ 
overview/ (last visited Sept. 1, 2013). 
125. See generally Gir et al., supra note 6; Lindroos et al., supra note 6, at  
284–85; see Herberts et al., supra note 70, at 11. 
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number of patients studied limited the ability to gauge the potential for 
adverse reactions or the potential recovery rate.127 
Celltex’s website does not describe the specific methodology the  
laboratory uses during the expansion process or disclose the substance of 
each additional agent it uses during the manufacturing process. However, 
Ra and colleagues state that Celltex uses FBS as a growth agent.128 As 
discussed above, FBS specifically poses numerous safety concerns, and 
even if processing can remove most of the FBS prior to clinical use, trace 
bovine proteins could remain sufficient to trigger an immune response 
and some contaminants (such as viruses, prions, and nanobacteria) are 
impossible to remove.129 If Celltex is utilizing a xeno-free serum or 
serum-free media, the scientific literature specifically notes that research 
of these alternatives is still in nascent stages, and these methods for 
expansion have not been shown to be safe or effective.130 Finally, any 
type of serum could become contaminated with yeast, fungi, and 
endotoxins, some of which are impossible to remove.131 Independent of 
methodology, the literature directly contradicts Celltex’s claims relating 
to established knowledge of the safety and efficacy of using MSCs for 
therapeutic purposes. 
In stark contrast to the FDA’s findings during the facility inspection, 
Celltex has also asserted that it rigorously follows the “highest quality 
control standards,” that “[n]o other corporation . . . does as much quality 
control,” and that the company’s quality assurance is unsurpassed.132 But 
rather than finding that Celltex employs the highest quality standards, 
the FDA concluded that it could not guarantee the uniformity, sterility, or 
viability of the cells the company manufactures.133  
Following Celltex’s emergence on the web, Professor Turner posted 
an in-depth examination of Celltex’s claims as compared to the FDA’s 
483 inspection report, linking each of Celltex’s assertions point by point 
to the report.134 Although Celltex claims that its cells are sterile, viable, 
 
127. Id. at 1306. 
128. See id. at 1298. 
129. Tekkatte et al., supra note 70, at 2, 10. 
130. Kinzebach & Bieback, supra note 87; Tekkatte et al., supra note 70. 
131. Tekkatte et al., supra note 70, at 2. 
132. Highest Quality Standards, CELLTEX THERAPEUTICS, http://www.celltex 
bank.com/advantage/quality (last visited May 20, 2013); Banking Basics, 
CELLTEX THERAPEUTICS, http://celltexbank.com/benefits/ basics (last  
visited May 20, 2013). 
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and intact, the 483 report shows that Celltex did not perform validation 
to ensure that the cells are viable, and it could not verify the final 
product.135 Celltex also assures customers of its safety by asserting that 
it takes steps to prevent the parasites, toxins, fungi, or bacteria from 
contaminating the final product.136 However, Turner noted that the 483 
report stated that Celltex failed to conform for cGMPs during the 
manufacturing process and it lacked quality control and validation 
procedures designed to prevent contamination.137 The FDA further found 
that Celltex failed tests for sterility and acceptable endotoxin levels and 
that it could not produce records of the destruction of cells that had 
previously failed this quality testing.138 Similarly, the inspection report 
stated that bacteria and fungi exceeded acceptable levels and that 
Celltex did not produce the expansion flasks to the FDA to check for 
contamination. Although Celltex’s procedures could not guarantee the 
viability, sterility, or safety of its cells, it continues to advertise to the 
contrary while charging patients $20,000 to $30,000 for potentially 
dangerous MSC injections.  
In addition to scrutinizing Celltex’s manufacturing process, Turner 
also questioned Celltex’s licensing partnership with RNL Bio whereby 
RNL’s lab technicians and scientists operate the Celltex laboratory. 
Turner maintains that Celltex’s assertion that it is at the forefront of 
“biosafety” is incompatible with “the disturbing corporate practices” of 
RNL.139 News headlines compiling RNL and its subsidiary’s activities 
suggest that their business practices are potentially misleading at best, 
and at worst, have likely caused patient injury and at least one reported 
death.140  
V. RNL, Stem Cell Tourism, and Lee v. Human Biostar 
To understand why Celltex’s advertisement claims are problematic, 
it is important to discuss RNL Bio and its Korean operations as well as 
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135. INSPECTION REPORT, supra note 133. 
136. Highest Quality Standards, CELLTEX THERAPEUTICS, http://celltexbank.com/ 
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137. Turner, supra note 134. 
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139. Turner, supra note 134. 
140. See David Cyranoski, Korean Deaths Spark Inquiry, 468 NATURE 485, 485 
(2010); Kim Tae-jong, Investigation Opens Over Stem Cell Treatments, 
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a recent lawsuit against its subsidiary RNL Life Science (also called 
Human Biostar) operating in Los Angeles, California.  
A. RNL Bio: Seoul, Korea 
In November 2010, Nature picked up on a story in the Korea Times 
reporting an investigation into the practices of RNL Bio, which was 
manufacturing and facilitating the injection of ASCs to patients in its 
Seoul office.141 Because Korean law prohibits the injection of ASCs into 
patients, RNL sent patients to affiliated clinics in China and Japan to 
receive the injections for a fee ranging from $9,000 to $27,000.142 In fact, 
Stanley Jones reported that he and his wife Kathi received their injec-
tions in Japan.143 According to reports by the Korea Times, RNL 
advertised that “a person who could not wake up can walk after the 
injection” and maintained that the injections would rejuvenate patients’ 
skin and body functions to that of a person decades younger.144 The 
amount of patients to whom Celltex provided injections is unclear. CEO 
Jeong Chan Ra reported to the media in 2010 that RNL had organized 
4900 customers for its medical tours since its opening three years prior.145 
However, in the company’s regulatory filing with the Korean Financial 
Supervisory Service, Ra cited a substantially higher number of 8000 
patients.146 Korea Times suggested that the discrepancy in the number 
of patients may have arisen from RNL providing the injections illegally 
in Korea.147 RNL officials, however, explained the 3000-patient difference 
arose because patient names may overlap or were omitted, and Ra 
denies facilitating any injections in Korea.148 Korea Times also alleged 
that RNL was suspected of providing free or reduced-rate ASC injections 
to politicians, celebrities, and powerful figures as a means of bargaining 
for relaxed industry regulations.149 Notably, Turner has highlighted 
Celltex’s similar affiliation with powerful figures such as Gov. Perry and 
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Rep. Hardcastle and pointed out these individuals’ similar efforts to 
change the legal landscape in Texas.150  
Around this time, the media and the Korean Ministry of Health and 
Welfare began to investigate complaints from patients and reports of the 
deaths of two patients who received ASC injections from RNL Bio 
coordinated by its Korea office in 2008.151 One patient, a seventy-three-
year-old man, received a treatment in Japan and died from a pulmonary 
embolism two months later; the second patient failed to awaken after 
receiving anesthetic during his injection procedure in China.152 Another 
patient came forward claiming he developed cancer several weeks 
following injections to “treat” his diabetes.153  
RNL Bio has vehemently denied that its injections caused, or could 
even contribute to, such injuries and deaths. In a press conference in 
Seoul, Ra argued that “[t]here has been no scientific evidence reported 
here or elsewhere that stem cell injections can be the cause of cancer or 
cardiovascular disease. In fact our studies with the Seoul National 
University suggest that stem cell injections rather help suppress such 
conditions.”154 Ra also asserted that facilitating injections for patients 
through other countries is inevitable, stating, ”If our client asks for the 
stem cell treatment, we must give them what they want.”155  
In stark contrast to Ra’s characterization, the scientific literature 
reviews discussed above conclude that both of the harmful outcomes 
constitute a risk from receiving the injections based on limited 
knowledge of clinical applications of ASCs for therapy and the intrinsic 
characteristics of stem cells. Literature widely cites the risk of tumor 
formation as one of the largest obstacles to using ASCs in clinical 
therapies.156 The scientific community is also unsure how many cells to 
inject to produce clinical benefit without exposing a patient to risks like 
pulmonary emboli or infarctions.157 MSCs can also differentiate into 
unwanted cell types, which can cause calcification or ossification in the 
heart, potentially leading to a myocardial infarction.158 Accordingly, 
literature supports the claims that the patients’ MSC injections could 
have, or did, contribute to cancer development and death.   
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The International Cellular Medicine Society (ICMS), an international 
non-profit organization dedicated to the advancement of stem cell 
treatments without governmental regulatory oversight, conducted an 
investigation into the patient deaths.159 ICMS concluded that the 
injections likely triggered the death of one patient, but for the other 
patient the cause of death was unknown.160 These findings, however, 
should be strongly scrutinized. ICMS promotes its agenda of providing 
autologous ASC treatments as the practice of medicine outside the scope 
of regulation, which means that significant problematic findings could 
hinder its goal of forgoing regulatory approval.  
ICMS also concluded that “[n]o evidence was found to suggest that 
inaccurate information caused either patient to give consent to medical 
procedures that they otherwise would not have given” and that the 
evidence suggests that “both patients were provided sufficient infor-
mation to give appropriate informed consent, and both did give 
consent.”161 Based on Ra’s characterization of benefits and risks in his 
media statements, this finding seems inaccurate. Ra inflated the promises 
of MSC injections and denied MSC injection risks against consensus in 
scientific literature. These failures fundamentally prevent a patient from 
making an informed decision and uncannily echo Jones’ statements to 
the media while promoting Celltex’s MSC injections. Scholars have 
noted deep conflicts of interest and questioned whether ICMS can 
impartially determine risks to patients or accurately report adverse 
events while holding strong ties to corporations that profit from permit-
ting injections.162 
Currently, the Ministry of Health and Welfare is investigating these 
claims along with whether RNL Bio’s practices comply with the  
requirements of the Korean Food and Drug Administration (KFDA).163 
As in the United States, the KFDA is still considering how to address 
the manufacturing and selling of MSCs with reference to the current 
framework for drugs.164 Although the KFDA would prohibit the sale and 
use of MSCs for treatment without its approval, such regulation would 
only apply if the MSCs are sold to and injected in patients in Korea.165  
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RNL Bio and Ra’s conduct is highly problematic. Based on Ra’s 
statements to the Korea Times and regulatory requirements set forth in 
Korean regulation, RNL Bio structured its corporate practices specifically 
to circumvent the KFDA’s regulatory requirements designed to oversee 
the manufacture, sale, and use of ASCs through a number of practices, 
including facilitating injections in other countries. As in the United 
States, these regulations are designed to assess potential risk of a 
product intended to treat disease and require the manufacturer to show 
the product’s safety and efficacy precisely because unregulated use of the 
product poses an unsatisfactory level of risk to patients. Ra’s public 
statements assume that the procedure constitutes an appropriate risk-
benefit calculation, which contradicts the consensus of the scientific 
literature. Further, it is doubtful whether patients understand that the 
general scientific community does not support Ra’s statements and that 
the injections pose such significant risks. Shirking corporate responsibility 
by adopting a consumer demand model is not only inappropriate but has 
likely resulted in actual harm to patients for which Ra denies any 
responsibility. For each of these reasons, Turner and other bioethicists 
have questioned RNL Bio’s business entanglement with Celltex and the 
company’s specific claims relating to its reputation.  
B.  RNL Life Sciences: Los Angeles, California  
In 2009, RNL Bio expanded and opened the subsidiary RNL Life 
Sciences’ corporate office in Los Angeles, California.166 RNL operates 
from an office in the Koreatown Galleria shopping mall that provides 
print and video testimonials showing happy and satisfied patients who 
received the MSC injections.167 RNL then coordinates an interstate and 
international process for obtaining, manufacturing, and injecting MSCs. 
According to Nature, patients visit an affiliated clinic in Los Angeles to 
undergo a procedure to remove adipose tissue that is sent to RNL’s 
Maryland lab for technicians to isolate mesenchymal cells.168 The RNL 
Maryland lab sends the mesenchymal cells to Seoul for culturing.169 RNL 
then recommends that patients travel to affiliated RNL clinics in China 
to receive their injections.170 Jane Shin, a “stem-cell” consultant with 
RNL Life Sciences, stated that 10,000 patients worldwide have paid for 
MSC injections, including 130 from the United States.171 Based on these 
figures, RNL and its subsidiaries have collected a total income of at least 
$75 million (a very conservative minimum estimate) from patients since 
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it opened for operation.172 Of these patients, some have received injec-
tions for serious conditions such as Parkinson’s disease, kidney failure, 
and diabetes, while RNL Life Sciences estimates that half of patients 
sought facial injections for anti-aging rejuvenation purposes.173  
RNL appears to have learned from previous media statements and 
has carefully tempered and crafted its representations of corporate 
services to the media. According to Jin Han Hong, President of RNL 
Life Sciences, RNL does not offer therapy but merely offers isolation and 
banking services.174 Hong also claims RNL does not guarantee the 
efficacy of the product, stating “we note the potential but we don’t make 
promises.”175 Hong also openly disagrees with the KFDA’s classification of 
ASCs as drugs, defending their practice and arguing that the MSCs RNL 
cultures and expands are “just part of the patient’s body.”176 However, 
both the FDA and scientific literature classify ASCs outside the scope of 
products that are merely part of the human body based on the level of 
manipulation and non-homologous use of the injected cells.  
C.  Lee v. Human Biostar 
Former customers of RNL Life Sciences have claimed that the  
company engaged in “unconscionable deceptive advertising” to promote 
its services.177 In May 2012, six individuals led by Ben Hang Lee filed a 
lawsuit against Human Biostar (formerly RNL Life Sciences), Hong, and 
Ra, alleging seven separate causes of action: (1) fraud and intentional 
misrepresentation of fact; (2) negligent misrepresentation of fact;  
(3) false advertising; (4) unfair competition; (5) financial elder abuse; (6) 
negligence; and (7) breach of implied covenant of good faith and fair 
dealing.178 The plaintiffs allege that they attended workshops sponsored 
by RNL in Los Angeles where Hong claimed that the MSC injections 
would cure all their ailments, including diabetes, arthritis, high blood 
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pressure, back pain and insomnia, while reversing aging and restoring 
their body functions to that of their twenties and thirties.179 According 
to the plaintiffs, Hong also assured them that the injections were 
“completely safe and risk free without any side effects or allergic reac-
tions, since patient’s own cells are transplanted back to the same 
patient.”180 Furthermore, the plaintiffs assert that Hong led them to 
believe that science has proven the MSC injections to be effective rather 
than experimental and that he charged $7500 to $8000 for each injec-
tion.181 The plaintiffs received either one or two injections.182 In the 
plaintiffs’ statement of facts, they allege that RNL marketed its product 
to them in Los Angeles and facilitated the process to receive injections in 
other countries such as Mexico, China, and even Korea, where regula-
tions prohibit injecting MSCs.183 Five of the six plaintiffs are over the 
age of sixty-five and allege that RNL represented the injections as a 
method of “turning back the clock” and “prevent[ing] future illness” for 
the elderly.184 Believing these representations, plaintiffs sought treatment 
for their specific health conditions and claim that the MSC injections 
were ineffective or even contributed to additional suffering.185  
The plaintiffs also question how RNL managed the process of trans-
porting and storing the cells prior to injection and claimed that despite 
the lengthy transportation of the MSCs, RNL failed to perform tests to 
ascertain the cells’ quality and freshness prior to injection.186 They also 
questioned whether the individuals who performed the injections actually 
had the appropriate training and qualifications to perform the proce-
dures.187 These specific allegations open the possibility of the plaintiffs 
asserting RNL exposed them to additional risks based on its manufactur-
ing and administration processes. If a corporation fails to closely monitor 
and regulate manufacturing, then the injection of ASCs poses additional 
and entirely distinct risks and raises potential complications for the 
recipient.188 Further, if the clinical staff fails to inject the cells correctly 
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during the procedure, improper administration may produce inappropriate 
differentiation or cellular migration contributing to tumor growth, emboli, 
or infarction.  
The plaintiffs request a variety of remedies, including compensatory 
and punitive damages, injunctive relief, restitution, and disgorgement of 
profits.189 In Count I, they allege that RNL knew that stem cell treat-
ment is only in the experimental phase; that the injections have not been 
approved for use in the US; and there is a lack of scientific evidence 
demonstrating that the treatment would cure the plaintiffs’ specific 
ailments, work to reverse aging, or prevent future illness.190 The plaintiffs 
claim that RNL induced them to rely on the company’s representations 
by concealing risk information.191 In Count III, the plaintiffs allege that 
RNL’s acts and omissions constitute false and misleading advertising 
under California state law, deceiving the general public as well as 
injuring the specific plaintiffs.192 In Count IV, the plaintiffs request an 
injunction, claiming that RNL promulgated unfair, deceptive, untrue, or 
misleading advertising that constituted an unlawful, unfair, or fraudulent 
business practice.193 The plaintiffs also invoke California law’s specific 
protections against financial elder abuse based on the anti-aging claims 
of the MSC injections.194 In Count VI, the plaintiffs assert that RNL 
owed to them a “duty of care to exercise reasonable skill and care in 
performance of their duties” and “knew or should have known that [a] 
failure to exercise [such] care” would harm the plaintiffs.195 In this claim, 
the plaintiffs reference the transportation, storage, and injection of cells, 
alleging that RNL failed to exercise ordinary care in harvesting, cultur-
ing, growing, storing, transporting, and administering the cells.196 
Both the plaintiffs’ claims and prayer for relief allege that RNL, 
Hong, and Ra created a business that intentionally misrepresents an 
experimental and unproven product to induce aging consumers or those 
with ailing health to purchase it as a miracle cure.197 It further charges 
consumers thousands of dollars to undergo a risky procedure that may 
not work or could cause grave health complications including cancer or 
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death.198 The plaintiffs allege that RNL’s injections were even more 
dangerous based on its negligent manufacturing and clinical practices. 
Accordingly, the plaintiffs request an injunction, disgorgement of profits, 
as well as exemplary and punitive damages.  
D.  Celltex’s Adoption of RNL’s Business Model 
RNL’s corporate practices in Korea and California raise a number of 
significant concerns and by association call into question Celltex’s claims 
of technological leadership, innovation, and biosafety. Celltex has 
engaged in a number of practices similar to those of RNL. From its 
inception, Celltex enlisted Governor Perry to publicly promote MSC 
injections and lobby (with Jones), the Texas Medical Board for relaxed 
regulations within the state.199 Similar to Ra and Hong, Perry and Jones 
have dismissed regulatory barriers to manufacturing and obtaining MSC 
injections.200 Jones and Eller structured Celltex in a manner to avoid 
requirements to demonstrate the product’s safety and efficacy through 
clinical trials prior to patient use, adopting a consumer demand model 
that would permit consumers to obtain the most “cutting edge” technol-
ogy. Celltex’s website even replicates RNL’s assertions that it merely 
offers expansion and banking services, which minimizes its powerful role 
of advertising and facilitating a risky medical procedure. Both RNL and 
Celltex charge patients a substantial sum for an unproven and potentially 
dangerous experimental therapy while targeting the aging, the ill, and 
even those seeking cosmetic procedures. It is possible that Jones may 
follow RNL’s lead in marketing anti-aging cosmetic procedures and 
attempt to capitalize on this massive market by linking Celltex’s services 
with his and his wife Kathi’s medical spa. Jones has also echoed Hong’s 
statements that MSCs are simply part of the patient’s body, assuaging 
the public and potential consumers.201 These statements mislead patients 
who may not understand the very significant risks inherent in injecting 
MSCs and the additional risks connected to a corporation’s failure to 
adhere to cGMPs during product manufacturing. Both Ra and Jones 
lauded MSCs’ efficacy while downplaying or denying the risks identified 
by a consensus of scientific literature.202 Perhaps most concerning, these  
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business practices have produced corporate profits at the expense of 
exposing patients to unacceptable risk and allegations of grave consumer 
injuries. Exploring RNL’s business model demonstrates the inappropri-
ateness of Celltex’s attempts to circumvent the FDA’s clear regulatory 
guidelines for MSCs. 
VI.  The FDA’s Authority to Regulate MSCs as  
Biological Products and Drugs in United States v. 
Regenerative Sciences 
At this time of writing, only one jurisdiction has examined how to 
interpret the FDA’s regulations relating to the sale and manufacture of 
autologous MSCs in United States v. Regenerative Sciences. Regenera-
tive Sciences is a company in Broomfield, Colorado that manufactures 
MSCs to treat a variety of orthopedic conditions in a procedure it called 
Regenexx.203 To create the MSCs, the company extracted and isolated 
cells in a patient’s bone marrow, processed the cells with growth factors 
derived from the patient’s blood and reagents and drug products, 
expanded them for several weeks in culture, and injected the MSCs into 
the patient at the site of injury.204 The treatment of two to four injection 
cycles reportedly cost $7000 to $9000.205  
In July 2008, the FDA sent a letter to Regenerative Sciences inform-
ing the company that it classified Regenexx as a drug and biological 
product based on Regenerative Sciences’ intent that the product would 
be used in the “diagnosis, cure, mitigation, treatment, or prevention of 
disease.”206 The letter also stated that Regenerative Sciences must obtain 
a biologics license to introduce its product into interstate commerce and 
submit an IND application demonstrating Regenexx’s safety and 
efficacy.207 Regenerative Sciences responded to the FDA’s letter by 
asserting that Regenexx was neither a biological product nor a drug and 
argued that the procedure merely constituted the practice of medicine, 
which the FDA has no authority to regulate.208 The FDA performed a 
facility inspection in 2009 and again the next year. In its first inspection, 
the FDA found numerous violations of current good manufacturing 
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practices.209 Prior to completing the inspection, Regenerative Sciences 
filed for a declaratory judgment and injunction to prevent the FDA from 
regulating Regenexx as a biological product and drug.210 The court 
dismissed the action for ripeness because the FDA had not issued a final 
administrative action.211 In 2010, the FDA inspected Regenerative 
Sciences once more, again finding violations of cGMPs.212 In August 
2010, the FDA announced its intention to seek an injunction preventing 
Regenerative Sciences from producing Regenexx because the company 
failed to make sufficient corrections to its manufacturing process.213 
When such an issue proceeds to litigation, courts generally defer to the 
agency’s interpretation of the regulations, especially where it is the 
agency’s area of expertise.214  
In district court litigation between the Department of Justice and 
Regenerative Sciences, Regenerative Sciences maintained that the 
manufacture and injection of MSCs constituted the practice of medicine, 
which is not within the FDA’s authority to oversee.215 The company 
further argued that the manufacture and injection of MSCs was outside 
the scope of the FDA’s authority to regulate as either a biological 
product or drug or under Section 361.216 Scholarly analysis of the case 
noted that FDA regulation does not infringe on the practice of medicine, 
but rather controls the products physicians use within the practice of 
medicine.217  
The FDA responded by reiterating the purpose of Section 361 and 
stressing the risks of contamination and infection posed by the  
processing of cells in culture.218 The FDA’s pleadings explained that the 
risk is two-fold because risks inhere based on both the products and 
reagents used during processing as well as the conditions of manufac-
ture.219 However, the FDA also asserted that expanding cells in culture 
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constitutes more than minimal manipulation and changes their relevant 
biological characteristics, meaning the cells do not meet the definition for 
a Section 361 product but rather fall under the regulatory category of 
biological products and drugs.220 As the FDA explained, 
culturing results in the selection and alteration of the original [cells] 
. . . because cells grow and respond to the tissue culture flasks and 
the composition of the media and other conditions under which they 
are grown . . . . [T]he remaining cells would expand in number and 
change so they are different from the original cells . . . [because] cul-
turing causes changes in the proteins and the genes expressed by the 
cells, as well as changes in the shape of the cells.221  
In July 2012, the District Court for the District of Columbia examined 
whether and how the FDA may regulate MSCs in United States v. 
Regenerative Sciences.222 The court rejected Regenerative Sciences’ claim 
that the manufacturing and injection of MSCs merely constituted the 
practice of medicine because the FDA controls the availability and 
method of manufacturing drugs for use prescribing by physicians, even if 
this regulation affects how physicians practice medicine.223 The court 
reiterated the FDA’s rationale for Section 361 regulation of HCT/Ps, 
finding that the FDA may regulate MSCs under Section 361 because 
autologous stem cells present a risk of spreading communicable disease.224 
Importantly, the court held that the method Regenerative Sciences used 
to process the MSCs constitutes more than minimal manipulation, which 
placed them under the FDA’s authority to regulate as biological prod-
ucts and drugs.225 Regenerative Sciences described the manufacturing 
process as “involv[ing] many steps, including selective culture and 
expansion of a multitude of different types . . . of cells using plastic 
flasks, additives and nutrients, and environmental conditions such as 
temperature and humidity, to determine the growth and biological 
characteristics of the resulting cell population.”226 The manufacturing 
process changed the biological characteristics of the cells, resulting in 
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more than minimal manipulation.227 Therefore, the court found that the 
FDA has proper authority to regulate Regenexx as a biological product 
and drug.228 It granted the FDA’s request for a permanent injunction 
until Regenerative Sciences can demonstrate that it complies with the 
appropriate regulatory requirements and ordered Regenerative Sciences 
to comply with the FDA’s subsequent decisions.229  
VII. Implications for Celltex and Physicians 
A. Celltex’s Position  
Regenerative Sciences is not binding in other jurisdictions, and  
Regenerative Sciences will likely appeal. However, the precedent estab-
lished by Regenerative Sciences holds that the FDA properly has 
authority to regulate MSCs such as those produced by Celltex, and the 
process of expanding the MSCs in culture during their manufacturing 
constitutes more than minimal manipulation, sweeping them into the 
regulatory category of biological products and drugs. Despite this 
finding, Celltex continued to advertise and provide services for MSC 
injections, even after the FDA’s 483-page inspection report classified it 
as a biological drug manufacturer. Celltex asserted, contrary to FDA 
policy and the inspection report, that it was merely a Section 361 
manufacturer and that it did not need to follow additional FDA  
requirements as a biological products or drug manufacturer.230 Celltex 
continues to argue that the FDA should regulate the MSCs under the 
Section 361 framework but at the time of publication has transferred the 
site of injections to Mexico.231 
B.  Texas Medical Board Rules 
In 2011, Jones, Perry, and Hardcastle initiated a lobbying effort in 
Texas to promote the ASC industry despite the FDA’s clear position 
that MSCs constitute biological products and drugs.232 After Jones 
performed Perry’s injections, Perry contacted the Texas Medical Board 
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at Jones’ behest, requesting that it promulgate rules to ensure that 
physicians would be permitted to perform stem cell infusions.233 Around 
the same time, Hardcastle, who also received MSC infusions from Jones, 
sent an email to the Board.234 Hardcastle stated that he did not intend 
to create “onerous and unnecessary regulations to impede the practice 
and research of physicians in regards to the use of investigational 
agents” and that Texas should work instead to protect “patients from 
unethical doctors using unproven treatments.”235 Hardcastle’s statements 
reflect misconceptions about the risks of the procedure, the infancy of 
clinical application, and the fact that ASCs are clearly defined as an 
unproven treatment.  
Together, these efforts appeared to be leading to codification of a 
legal avenue for physicians to inject patients with MSCs while Celltex 
could challenge the FDA’s method of regulating MSCs. The draft of the 
rules proposed to permit physicians to use investigational agents to treat 
their patients as long as the physician enrolled the patient into a study 
protocol approved by an Institutional Review Board (IRB) or submitted 
an investigational new drug application (IND) to the FDA.236 The FDA 
requires manufacturers of biological products and drugs to both submit 
an IND and obtain IRB approval of the research protocol. If the physi-
cian followed these rules, his actions would constitute the practice of 
medicine, and he could not be found guilty of unprofessional conduct or 
failure to practice medicine in an acceptable manner.237 Thus, if a 
physician found an IRB to approve a research protocol designed to study 
MSC injections, then he could attempt to insulate himself from profes-
sional sanction or liability arising out of injecting patients with risky, 
unproven “therapies.”  
The media in Texas took note of the Board’s anticipated attempt to 
circumvent the FDA’s requirements and questioned its authority to 
promulgate such a rule.238 The San Antonio Express highlighted Perry’s 
high level of influence within the Board—Perry appointed eighteen of 
the Board’s nineteen members—suggesting that Perry attempted to 
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forcefully steer the outcome of the rulemaking.239 Perry previously 
appointed Jones to the Board, and Jones subsequently sought to 
influence the rulemaking session that would ultimately and substantially 
affect his business and his medical license.240 As discussed above, the 
relationships between key figures suggested an inappropriate level of 
policymaking influence with the intention to promote the ASC industry: 
Eller contributed to Perry’s political campaign; Jones and Perry are 
close friends; Jones injected Perry with MSCs contrary to FDA policy; 
and both Eller and Jones stand to reap significant financial benefits, of 
which they may choose to contribute to Perry’s future political career.  
During the rulemaking session, a number of interested individuals 
submitted comments to the Board, including members of the public, 
Turner, and Jones.241 Professor Turner submitted a lengthy comment to 
the Texas Medical Board listing seven substantive concerns regarding 
the rule and the potential conflict of interest relating to Jones’ influence 
in the Board’s decision-making process.242 He reiterated that the FDA 
has asserted its authority to regulate ASCs, requiring an investigator in 
a clinical trial studying MSC injections to submit a protocol to both an 
IRB and the FDA.243 Turner also took the position that ASC injections 
as a subset of “investigational agents” do not constitute the practice of 
medicine using proven therapies but rather should be classified as 
experimental research subject to clinical trials to determine their safety 
and efficacy. Importantly, Turner connected this classification and the 
cost of accessing MSC injections to the potential for “therapeutic 
misconception.”244 As evidenced by other public comments, patients may 
wrongly believe that the medical field classifies MSC injections as a safe 
and effective therapy if a physician performs the injections as a medical 
practice.  
In April 2012, the Texas Medical Board passed the rule with a small 
but important revision.245 The Board revised the rule’s definition of 
“investigational agent” to exclude PHSA Section 351 and 361 products 
as well as products defined as drugs and biologics under the FDCA.246 
Overlooked by most mainstream media, this minor revision held tremen-
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dous impact by excluding physicians who may inject MSCs from the 
rule’s applicability.247 Accordingly, the rule in effect will have no change 
on what steps physicians are required to take to perform MSC injections 
if the manufacturer classifies them as a Section 361 product or a biologi-
cal product or drug.  
The reason for the Board’s sudden revision is unclear, but it could 
creatively protect physicians who are performing the injections in the 
interim while Celltex challenges the FDA’s classification of its MSCs. 
Celltex may challenge the FDA’s classification and the FDA’s attempts 
to enforce its requirements for MSCs through litigation, similar to 
Regenerative Sciences, with the hope of an alternate outcome in a 
different jurisdiction. Physicians performing the injections may strategi-
cally choose to enroll patient recipients into a clinical protocol to build 
evidence of responsible professional conduct or as insurance against 
sanction. It is also foreseeable that patients in Texas may come forward 
alleging injuries arising from the injections and attribute them to 
physician wrongdoing. Physicians could counter such anticipated claims 
by demonstrating they acted above the necessary requirements because 
they enrolled patients into an IRB-approved protocol even when not 
required and should accordingly not be found guilty of unprofessional 
conduct or failure to practice medicine in an acceptable manner. Such a 
provision undermines the accountability, transparency, and trust that 
should drive physician and patient interactions relating to the use of 
experimental agents such as MSCs.  
 
C.  Physician Duty and Texas State Law 
1.  Ethical Duties and the Purpose of the State Medical Board 
Using the state medical board as a creative legal strategy runs  
contrary to the Board’s purpose, physicians’ ethical duties toward their 
patients, and Texas state law. According to the American Medical 
Association, physicians must act in the best interest of their patients 
while upholding the duty not to harm their patients.248 Furthermore, 
respecting a patient’s autonomy requires a physician to protect and 
foster a patient’s choices that arise from appropriate disclosure and 
informed consent.249 Based on Jones’ statements to the media and the 
Board, it is uncertain whether patients seeking Celltex’s MSC injections 
are fully informed of the serious medical risks and the uncertain clinical 
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benefit for which they pay thousands of dollars. Performing such 
injections is arguably not acting in the best interest of patients because 
there is no guarantee of the MSCs safety and efficacy outside of the 
FDA’s approval process. Potentially more troubling, performing such 
injections prior to sufficient research into clinical applications could 
cause grave harm and even death, both outcomes that have already 
surfaced in allegations against RNL’s products.  
The state medical board as an entity is designed to constrain the 
amount of risk to which physicians may expose their patients when 
opting to use experimental therapies. It need not accept emerging 
medical viewpoints as an appropriate standard of patient care.250 Accord-
ingly, if a state medical board concludes that a physician’s judgment 
exposes a patient to risks stemming from experimental treatment that 
are not outweighed by potential benefit, then the board ordinarily may 
find that the physician failed to practice medicine in an acceptable 
manner.251 In this case, however, a physician who chooses to inject an 
improperly regulated product into patients is not merely an emerging 
viewpoint in experimental therapy but is acting contrary to the FDA’s 
regulatory requirement that MSCs must first satisfy enumerated and 
unambiguous requirements for biological products and drugs. These 
products pose such a risk of patient harm that manufacturers must 
adhere to specific regulatory requirements prior to wide-scale clinical use 
by physicians. Members of the Texas Medical Board should exercise 
independent discretion and eliminate potentially inappropriate influence 
from Jones and Perry in future decisions relating to physician conduct 
and standards for using ASCs in patients that have not been approved 
by the FDA. 
2.  Professional Sanction or Liability for Physicians Performing Injections  
Texas law already contains several provisions that may subject phy-
sicians to professional sanction or civil liability arising from injecting 
patients with MSCs. The Texas Occupational Code provides that the 
Board may discipline a physician who commits unprofessional or 
dishonorable conduct that is likely to deceive, defraud, or injure the 
public.252 Accordingly, a physician who represents to patients that the 
MSC injection procedure entails minimal risk or makes statements 
suggesting the worst that may happen is that the procedure will not 
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work could be subject to potential professional sanction because such 
conduct is both dishonest and likely to deceive the public. Notably, to 
subject a physician to professional sanction, a patient need not suffer 
actual injury.253 Thus, the Board is not required to wait until patients 
undergoing MSC injections develop cancer, suffer myocardial infarctions, 
or even die from MSC-related complications to subject the physician to 
professional sanction. 
In Texas and other states, if a physician deviates from the standard 
of care and subjects patients to undue risk of harm, the physician may 
also be civilly liable through claims for medical malpractice.254 The Texas 
Occupational Code specifies that failure to practice medicine in an 
acceptable professional manner consistent with the public health and 
welfare includes failing to treat patients according to the generally 
accepted standard of care.255 Case law has clarified that a physician 
merely deviating from the standard of care or violating an accepted 
medical standard is sufficient to satisfy this statutory definition.256 Thus, 
if the majority of physicians would not inject their patients with MSCs 
from manufacturers unless those manufacturers abide by the FDA’s 
regulatory scheme, then that is standard of care. Furthermore, if a 
physician fails to safeguard against additional complications, then this 
may serve as additional evidence of failing to practice medicine in an 
acceptable professional manner.257 Additional complications from using 
MSCs may arise from the intrinsic nature of using stem cell manufacturing 
processes for validation and quality control and corporate practices to 
ensure compliance with cGMPs to mitigate the occurrence of avoidable 
risks such as cell contamination. If a physician injects MSCs that have 
not been adequately studied for their effects in a clinical population and 
is unsure whether the manufacturing process takes steps to ensure the 
cells are sterile, viable, and free from contamination, then the physician 
may be failing to safeguard the patient against foreseeable complications. 
However, if a physician continues to inject MSCs even after the FDA 
has inspected the facility (as with Celltex) and found that the facility 
could not guarantee the cells’ sterility, uniformity, viability, or integrity, 
then the physician knowingly exposes the patient to such additional 
foreseeable complications.  
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Although these state law provisions exist as disincentives for physi-
cians to perform the injections, such provisions may be insufficient to 
adequately deter physicians or address injury arising from a large 
commercial operation.258 Plaintiff litigation as a retrospective strategy 
constitutes an imperfect method of regulation because some injuries may 
be irreversible, or the injections may result in patient death, as alleged 
against RNL Bio, for which any recovery through litigation would never 
be sufficient. Lastly, litigation is a costly and time-consuming process 
that many patients may not have the means or ability to pursue.259 
Rather than retrospectively regulating the system according to patient 
harm, the FDA should enforce its regulatory power over MSC manufac-
turers to require compliance by injunction and court order if necessary.  
D. FDA’s Enforcement Action: Warning Letter to Celltex  
In September 2012, the FDA sent a warning letter to Celltex main-
taining that the MSCs it manufactures are not solely regulated as 
Section 361 products.260 The letter specified that Celltex’s processing 
“alters the original relevant characteristics of the adipose tissue relating 
to the tissue’s utility for reconstruction, repair, or replacement,” which 
means it does not fall under the category of “minimally manipulated.”261 
Thus, the product would likely not meet the regulatory requirements 
showing homologous use.262 The letter further observed that because 
Celltex holds out its product to consumers as a drug, it must be regulated 
under the more stringent regulatory framework.263 Finally, the letter 
referenced the lengthy list of good manufacturing practice areas originally 
brought to Celltex’s attention in the 483 inspection report that Celltex 
failed to remediate and correct to the FDA’s satisfaction.264  
Celltex responded to FDA’s letter the next month with a detailed 
explanation of disagreement and requested a meeting to discuss the 
impact of the FDA’s decision on precedent in this area of research.265 
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First, Celltex reframed the examination of the item being manipulated 
during the extraction and expansion process, arguing that the FDA 
should not consider the adipose tissue but rather the product extracted 
from that tissue—the MSCs—when considering whether the final 
product was minimally manipulated.266 Second, by using MSCs as the 
initial material, Celltex asserted the purpose of the injected MSCs 
constitutes homologous use.267 According to Celltex’s argument, because 
MSCs are inherently multi-potent, anti-inflammatory, immune-
modulatory injections, adhering to these purposes are homologous.268 
Celltex’s arguments attempt to support that the drug and biological 
framework is “excessive” for MSCs and that the company wants to 
negotiate the ability to continue utilizing the Section 361 framework.269 
Finally, Celltex deferred to RNL Bio to provide the appropriate materials 
to the FDA to demonstrate corrective efforts related to the areas of 
noncompliance set forth in the 483 inspection report.270  
Despite Celltex’s attempt to convince the FDA to allow it to continue 
manufacturing the MSCs under the Section 361 framework, the FDA has 
held strongly to its stance that it will regulate MSCs within the frame-
work as a drug and biological product. As discussed above, the FDA’s 
categorization already accounts for analyzing how expansion and 
processing changes the biological characteristics of MSCs. The court in 
Regenerative Sciences adopted the FDA’s arguments that the process of 
culturing and expanding MSCs changes their relevant biological charac-
teristics, which constitutes more than minimal manipulation and places 
them in the category of drugs and biological products.271  
Shortly after the FDA’s enforcement action through the warning 
letter, Celltex announced it would cease injecting patients in the United 
States.272 In January 2013, Celltex publicly announced it had changed its 
operational structure to facilitate patient travel to Mexico to receive 
injections while coordinating regulatory compliance for its future 
injections in the United States.273 Despite Celltex’s geographical separa-
tion as a means to circumvent the FDA’s regulation of MSC injections, 
the procedure still poses considerable concerns related to safety, efficacy, 
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and unacceptable level of risk to patients. As the plaintiffs in Lee v. 
Human Biostar allege, relocating the injection clinic does not remove the 
risk of numerous harms to patients, nor should it discharge the corpora-
tion from potential liability arising from patient injuries.274  
Conclusion 
Governor Rick Perry and Dr. Stanley Jones lauded Celltex’s MSCs 
to the media while downplaying the potential for clinical inefficacy and 
denying significant safety risks. The FDA has definitively stated that it 
classifies autologous MSCs that are more than minimally manipulated 
and intended for non-homologous use as drugs and biological products 
under the FDCA and PHSA—not merely Section 361 products.  
MSCs by their nature are inherently risky, and scientific literature 
describes the barriers to safety and efficacy in their clinical use. In 
addition to intrinsic risks, MSCs also present challenges associated with 
clinical application such as mitigating the occurrence of life-threatening 
immune reactions, myocardial infarction, benign and cancerous tumor 
formation, transmission of disease, and death. Manufacturers’ failure to 
adhere to cGMPs and control processing conditions exponentially 
increases these risks and the resulting cells may lack viability, stability, 
or even pose threats of contamination to the recipient. Despite alarming 
findings during the FDA’s facility inspection, Celltex dismissed the 
FDA’s serious observations relating to cGMP noncompliance and issued 
media claims related to its manufacturing practices, scientific advances, 
and product safety. 
Celltex’s licensing partnership with RNL Bio raises additional con-
cerns based on RNL and its subsidiaries’ corporate practices. RNL Bio 
and RNL Life Sciences overstated the therapeutic promise of its MSC 
injections and denied serious risks against the consensus found in 
scientific literature. Both RNL Bio and RNL Life Sciences structured 
operations specifically to circumvent federal regulatory requirements and 
adopted a consumer demand model, leading former patients of both 
operations to allege adverse health consequences including cancer and 
death. Jones and Eller have adopted a number of corporate strategies 
from RNL and structured Celltex to avoid regulatory approval while 
standing to gain sizable profits from the ill, the aging, and other vulner-
able patient populations. 
In July 2012, the District Court for the District of Columbia set 
guiding precedent for companies such as Celltex that are attempting to 
challenge the FDA’s categories for regulating MSCs under the PHSA 
and the FDCA. Regenerative Sciences agreed with the FDA’s regulatory 
classification, holding that the number of reagents, the extensive process, 
and the change in cell biology during the manufacture of MSCs indeed 
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constitutes more than minimal manipulation, thus placing the product 
under the FDA’s authority to regulate.  
Despite serious patient allegations against RNL and the Regenerative 
Sciences ruling, Celltex continues to challenge the FDA’s authority and 
regulatory classification of its product and openly markets its MSCs 
through its website to facilitate travel to receive injections in Mexico as 
a means of evading the scope of FDA’s regulatory power. Although 
Perry and Jones may have strategically attempted to modify Texas 
Medical Board rules in their favor, such a strategy runs contrary to 
physicians’ ethical and legal duties to their patients and undermines the 
accountability and trust that should govern physician-patient interac-
tions. Finally, as allegations against RNL demonstrated, former patients’ 
litigating as a method to address consumer injury is an imperfect 
solution, which future Celltex patients who receive injections in Mexico 
may also encounter. The FDA must continue to enforce its authority 
over Celltex’s MSCs injected in the United States to prevent patients 
from a product that may be inefficacious, or worse, a highly unsafe 
product that could potentially transmit viruses or endotoxins, induce a 
potentially fatal immune reaction, create tumors, or cause death. 
